DDrare: Database of Drug Development for Rare Diseases

16. クロウ・深瀬症候群
［臨床試験数：12，薬物数：18（DrugBank：8），標的遺伝子数：5，標的パスウェイ数：79］

Searched query = "Crow-Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Cyclophosphamide; Daratumumab; Daratumumab Injection; Dexamethasone; FPF 300 (thalidomide); G-CSF; Ixazomib; Ixazomib Citrate; Lenalidomide; Lenalidomide and dexamethasone; Lenalidomide+Dexamethasone; Lenalidomide, Dexamethasone; Lenograstim; Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration; REVLIMID*21CPS 25MG; Revlimid; Thalidomide

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02193698 (ClinicalTrials.gov)	July 2014	16/7/2014	Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial	Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome	POEMS Syndrome	Drug: Lenalidomide +Dexamethasone	Chiba University	NULL	Completed	20 Years	N/A	Both	5	Phase 2	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02193698
(ClinicalTrials.gov)

July 2014

16/7/2014

Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial

Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome

POEMS Syndrome

Drug: Lenalidomide +Dexamethasone

Chiba University

NULL

Completed

20 Years

N/A

Both

Phase 2

Japan